Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Leukotriene A4 methyl ester

Substrate for LTA4 hydrolase and LTC4 synthase
 
BML-LA004-0050 50 µg 311.00 USD
 
BML-LA004-1000 1 mg 5,280.00 USD
Do you need bulk/larger quantities?
 
Unstable intermediate in the biosynthesis of LTB4 and LTC4. The naturally occuring free acid is a substrate for LTA4 hydrolase and LTC4 synthase and plays a central role in transcellular leukotrieneand lipoxin biosynthesis. Mobilizes Ca2+ in human neutrophils. Supplied as the methyl ester for greater stability.

Product Specification

Alternative Name:LTA4-ME
 
Formula:C21H32O3
 
MW:332.5
 
Source:Synthetic.
 
CAS:73466-12-3
 
Concentration:1 mg/ml
 
Formulation:Oil dissolved in 2% triethylamine/hexane.
 
Purity:≥95% (HPLC) (remainder 11-trans isomer)
 
Appearance:Liquid.
 
Shipping:Shipped on Dry Ice
 
Long Term Storage:-80°C
 
Use/Stability:Stable for at least 1 year after receipt when stored, as supplied, at -80°C.
 
bml-la004
Please mouse over
bml-la004

Product Literature References

Ca2+ mobilization with leukotriene A4 and epoxytetraenes in human neutrophils: F. Luscinskas, et al.; Biochem. Pharmacol. 39, 355 (1990), Abstract;
Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils: S. Fiore & C. N. Serhan; J. Exp. Med. 172, 1451 (1990), Abstract; Full Text
Enzymes involved in the biosynthesis of leukotriene B4: B. Samuelsson & C. D. Funk; J. Biol. Chem. 264, 19469 (1989), Abstract; Full Text
Leukotrienes and lipoxins: structures, biosynthesis, and biological effects: B. Samuelsson, et al.; Science 237, 1171 (1987), Abstract;

Related Literature

Technical Posters
Arachidonic Acid Metabolites
Arachidonic Acid Metabolites
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,